title: Advanced glycation end products (AGE) and the receptor for AGE are present in gastrointestinal tract of familial amyloidotic polyneuropathy patients but do not induce NF-kappaB activation.
abstract: Familial amyloidotic polyneuropathy (FAP), Portuguese type, is a hereditary amyloidosis caused by mutated transthyretin (ATTR) in which an exchange of valine for methionine at position 30 has taken place (ATTR Val30Met). Gastrointestinal complications, such as nausea, diarrhoea and malabsorption, have a significant impact on survival since the cause of death in the majority of cases is a consequence of extreme malnutrition due to dysmotility of the gastrointestinal tract. Recently, a role of the receptor for advanced glycation end products (RAGE) has been implicated in amyloid toxicity. Transthyretin (TTR) amyloid fibrils have been shown to have affinity for RAGE and subsequently induce NF-kappaB activation and apoptosis. Since gastrointestinal dysfunction plays an important role in FAP, we wanted to investigate if amyloid toxicity in the gastrointestinal tract is related to RAGE, NF-kappaB activation and apoptosis. Gastrointestinal tract autopsy samples were studied for the distribution of amyloid, RAGE, advanced glycation end products (AGE) and NF-kappaB. Furthermore, we examined the immunoreactivity of an apoptotic marker to investigate if an apoptotic pathway contributes to amyloid toxicity. The distribution of RAGE and AGE strongly correlated to that of amyloid deposits. Sequential immunofluorescence staining revealed a clear relationship between TTR, AGE and RAGE. No correlation between NF-kappaB, apoptotic marker and amyloid deposits was found. We conclude that RAGE-AGE or RAGE-TTR interaction might play important roles for gastrointestinal dysfunction and amyloid toxicity, although not through NF-kappaB activation and apoptosis.
authors.affiliation: Gastroenterology and Hepatology Section, Department of Medicine, Umeå University Hospital, 901 85 Umeå, Sweden.
authors.forename: Noriko
authors.initials: N
authors.lastname: Matsunaga
authors.forename: Intissar
authors.initials: I
authors.lastname: Anan
authors.forename: Sture
authors.initials: S
authors.lastname: Forsgren
authors.forename: Ryoji
authors.initials: R
authors.lastname: Nagai
authors.forename: Peter
authors.initials: P
authors.lastname: Rosenberg
authors.forename: Seikoh
authors.initials: S
authors.lastname: Horiuchi
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ando
authors.forename: Ole B
authors.initials: OB
authors.lastname: Suhr
mesh_terms: D000328:Adult; D000682:Amyloid / Q000378:metabolism; D028227:Amyloid Neuropathies, Familial / Q000150:complications / Q000378:metabolism*; D017209:Apoptosis; D005260:Female; D005767:Gastrointestinal Diseases / Q000209:etiology / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B / Q000378:metabolism; D011228:Prealbumin / Q000378:metabolism; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*
chemical_list: D000682:Amyloid; D017127:Glycation End Products, Advanced; D016328:NF-kappa B; D011228:Prealbumin; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic; C076571:transthyretin-related amyloid fibril protein, human